1. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Piprot, C; Cals, L; Chaigneau, L; Demarchi, F; N'Guyen, T; Stein, U; Villanueva, C; Bréau, JL; Chouahnia, AK; Saintigny, P; Boué, F; deSaint-Hilaire, P; Guimont, I; Grossat, N; Valenza, B; Lévy, E; Médioni, J; Delbaldo, C; Grenier, J; Pouessel, D Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Issue 10191 (29th June 2019) Authors: Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, Pierre; Serin, Daniel; Jacquin, Jean-Philippe; Jouannaud, Christelle; Rios, Maria; Abadie-Lacourtoisie, Sophie; Venat-Bouvet, Laurence; Cany, Laurent; Catal... Journal: Lancet Issue: Volume 393:Issue 10191(2019) Page Start: 2591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 972PBcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC). (23rd October 2018) Authors: Brachet, P E; Joly Lobbedez, F; Fabbro, M; Leary, A; Medioni, J; Follana, P; Lesoin, A F; Frenel, J-S; Abadie Lacourtoisie, S; Floquet, A; Gladieff, L; You, B; Gavoille, C; Kalbacher, E; Briand, M; Just, P A; Blanc-Fournier, C; Giffard, F; Clarisse, B; Poulain, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. (9th March 2019) Authors: Joly, F; Ahmed-Lecheheb, D; Kalbacher, E; Heutte, N; Clarisse, B; Grellard, J M; Gernier, F; Berton-Rigaud, D; Tredan, O; Fabbro, M; Savoye, A M; Kurtz, J E; Alexandre, J; Follana, P; Delecroix, V; Dohollou, N; Roemer-Becuwe, C; De Rauglaudre, G; Lortholary, A; Prulhiere, K Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P01.15.A Longitudinal assessment of neurocognition and quality of life in low-grade glioma patients receiving first-line Temozolomide. (5th September 2022) Authors: Darlix, A; Fabbro, M; Monnier, M; Castan, F; Coutant, L; Denis, E; Carriere, M; Menjot de Champfleur, N; Rigau, V; Duffau, H; Guerdoux, E Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P04.02 Postponing the medical treatment is possible in selected cases of diffuse low-grade glioma with foci of WHO grade III-IV after total or subtotal resection. (6th September 2019) Authors: Darlix, A; Rigau, V; Fraisse, J; Gozé, C; Fabbro, M; Duffau, H Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P11.19.B Bevacizumab in recurrent WHO grade 2-3 gliomas. (5th September 2022) Authors: Annakib, S; Rigau, V; Darlix, A; Gozé, C; Duffau, H; Bauchet, L; Mollevi, C; Fabbro, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting. (6th September 2019) Authors: Lesueur, P; Damaj, G; Hoang-Xuan, K; Rolland, V; Schmitt, A; Chinot, O; Fabbro, M; Agapé, P; Chabrot, C; Chebrek, S; Feuvret, L; Stefan, D; Soussain, C; Houillier, C Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. (1st November 2019) Authors: Harter, P; Mouret-Reynier, MA; Pignata, S; Cropet, C; González-Martin, A; Bogner, G; Fujiwara, K; Vergote, I; Colombo, N; Mäenpää, J; Floquet, A; El-Balat, A; Lorusso, D; Guerra Alia, EM; Fabbro, M; Schmalfeldt, B; Hardy Blessard, AC; Runnebaum, I; Pujade-Lauraine, E; Ray-Coquard, I Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗